Why the study?
Despite preclinical validation and clinical translation, ischemic stroke remains a leading cause of death and disability, with interconnected thrombosis and inflammation driving cerebral vessel occlusion and damage.
This review highlights the interconnected processes of thrombosis and inflammation in ischemic stroke and summarizes emerging therapeutic approaches targeting thromboinflammation currently in clinical trials.
Thromboinflammation remains a key stroke pathway; leaves open targeted dual-therapy trials.
Despite decades of promising preclinical validation and clinical translation, ischemic stroke still remains as one of the leading causes of death and disability worldwide. Within its complex pathophysiological signatures, thrombosis and inflammation, that is, thromboinflammation, are highly interconnected processes leading to cerebral vessel occlusion, inflammatory responses, and severe neuronal damage following the ischemic event. Hence, we here review the most recent updates on thromboinflammatory-dependent mediators relevant after stroke focusing on recent discoveries on platelet modulation, a potential regulation of the innate and adaptive immune system in thromboinflammation, utterly providing a thorough up-to-date overview of all therapeutic approaches currently undergoing clinical trial.
No takes yet. Share an insight, caveat, or question.
Meyer et al. (2022) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: